Post-Market Surveillance in Guatemala: Fees Include Sanitary Vigilance and NT 36 Market Checks

1. Key takeaways

Post-market oversight in Guatemala rests on two clear statutory anchors. The first is at the fee level: Article 5.1.1 and Article 9.4 of NT 37 state that the official fees for registration and renewal already include sanitary vigilance (vigilancia sanitaria). The second is at the standard level: NT 36 Versión 06-2023, “Vigilancia de Mercado de Productos Farmacéuticos y Afines” (market surveillance of pharmaceutical products and related products), entered into force on 2023-07-21. Read together, these two anchors carry a single message: registration is not the end point of the process, because surveillance is part of what the registration fee pays for. A company that treats market entry as a one-off approval exercise and budgets only for the dossier has mispriced the obligation. The fee structure signals that the regulator considers surveillance a continuing service attached to the certificate, and the operational work of remaining surveillance-ready — documented quality controls, conditions of sale that match the approval, and records that can withstand an inspection — stays with the certificate holder for as long as the registration remains valid, while the separate NT 36 standard defines how the surveillance service is exercised in practice.

2. Legal basis

The documents below form the legal basis for market surveillance in Guatemala. The fee provisions of NT 37 establish that surveillance is financed through the registration and renewal fees, while NT 36 Versión 06-2023 supplies the operative market surveillance standard, and the cancellation provisions of NT 37 supply the consequences when surveillance finds problems. Each entry in the table is drawn from the current published text of the relevant standard, and the two fee articles should be read together with the cancellation provisions, because they define both the financing and the enforcement side of the same surveillance system.

3. Expert insights

Insight 1: Writing the cost of surveillance into the official fee is a deliberate institutional choice. Article 5.1.1 and Article 9.4 both repeat the phrase “contempla también la vigilancia sanitaria”. This repetition is not incidental drafting; it positions surveillance as a component of the registration service itself. When a company estimates the cost of market access in Guatemala, it should not expect the surveillance stage to be provided separately and for free. The budget line for post-market compliance is, in effect, already inside the fee schedule, and the operational work of being surveillance-ready remains the company’s own responsibility.

Insight 2: NT 36 covers pharmaceutical and related products, which is how devices are brought within scope. In Guatemala, medical devices are classified as related products (productos afines). The title of NT 36 expressly includes “Productos Farmacéuticos y Afines”, so devices fall within the coverage of this standard. This fills a gap, because NT 37 itself does not contain a dedicated chapter on post-market surveillance. Companies should therefore read NT 36 as the operative surveillance text for their device portfolio, not as a pharmaceutical-only document. For a device manufacturer, this means that sampling, inspection and market checks conducted under NT 36 apply to its products on the same footing as to medicines, and that surveillance findings can feed directly into the cancellation grounds discussed below.

Insight 3: Surveillance and cancellation operate as means and result. The four cancellation grounds in Article 11 (products shown to be harmful or unsafe, falsified documentation, failure to meet quality controls, and sale under different conditions) and the automatic cancellation in the Annex 2 note are the processing outlets when surveillance finds problems. NT 36 provides the discovery mechanism; Article 11 provides the legal basis for acting on what is discovered. A compliance program should connect the two: every surveillance finding should be assessed against the cancellation grounds, and the assessment should be documented so that the company can respond to the authority from a written record rather than from memory.

Insight 4: NT 36 is part of the dense wave of 2023 revisions. Standards that took effect in the same year include NT 5 v03-2023 (manufacturing laboratories, 2023-03-21), NT 07 v05-2023 (wholesalers, 2023-07-21), NT 21 v02-2023 (pharmaceutical labelling, 2023-09-01), NT 67 v6-2023 (biological products, 2023-07-20) and NT 77 v08-2023 (2023-06-27). The year 2023 was a concentrated version-change year for standards on related products in Guatemala, and companies should treat NT 36 as one element of that systemic update rather than an isolated text.

4. Practical recommendations

• Treat post-market surveillance as a service already paid for, and proactively build internal inspection mechanisms that match the surveillance requirements.
• Run an annual self-check against the four cancellation grounds in Article 11, with particular attention to whether sales conditions match the approved conditions.
• Follow the specific inspection methods of NT 36 v6-2023 and maintain communication with the LNS sampling arrangements.
• Keep a version ledger of the standards revised in 2023 and confirm that every referenced version is the current one.
• Link corrective actions arising from surveillance findings to the change procedure of Article 6, so that remediation is never used as a substitute for a required change filing.

5. Verification checklist

• □ Confirmed that the official fees include sanitary vigilance (Articles 5.1.1 and 9.4)
• □ Confirmed that NT-36 v6-2023 entered into force on 2023-07-21
• □ Annual self-check against the four grounds of Article 11 completed
• □ Version ledger established for the standards revised in 2023
• □ Surveillance remediation linked to the change procedure of Article 6

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Guatemalan market. Our team manages Ministry of Public Health and Social Assistance (MSPAS) registrations, coordinates import and distributor requirements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com